MAGEA3 and melanoma: In another melanoma clinical trial, Banchereau et al. (11) evaluated immune and clinical responses in 18 patients with metastatic melanoma after injecting DCs pulsed with peptides (MART-1, tyrosinase, MAGE-A3, and gp100) subcutaneously.